Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AYRWF OTCMKTS:GPLB NASDAQ:QLGN NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYRWFAyr Wellness$0.03+22.7%$0.09$0.00▼$2.60$3.14M1.69586,193 shs183,059 shsGPLBGreen Planet Bioengineering$0.04$0.04$0.02▼$0.70$800K3.073,055 shsN/AQLGNQualigen Therapeutics$1.87+7.8%$2.41$1.61▼$10.45$3.16M-0.15343,835 shs60,216 shsRDHLRedhill Biopharma$1.51+6.3%$1.60$1.06▼$12.19$3.47M4.25290,012 shs56,517 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYRWFAyr Wellness-20.86%-6.38%+10.00%-82.43%-98.98%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-63.64%-91.80%QLGNQualigen Therapeutics0.00%-3.35%-4.95%-54.47%-77.68%RDHLRedhill Biopharma-1.39%+9.23%+22.41%-29.00%-86.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYRWFAyr Wellness$0.03+22.7%$0.09$0.00▼$2.60$3.14M1.69586,193 shs183,059 shsGPLBGreen Planet Bioengineering$0.04$0.04$0.02▼$0.70$800K3.073,055 shsN/AQLGNQualigen Therapeutics$1.87+7.8%$2.41$1.61▼$10.45$3.16M-0.15343,835 shs60,216 shsRDHLRedhill Biopharma$1.51+6.3%$1.60$1.06▼$12.19$3.47M4.25290,012 shs56,517 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYRWFAyr Wellness-20.86%-6.38%+10.00%-82.43%-98.98%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-63.64%-91.80%QLGNQualigen Therapeutics0.00%-3.35%-4.95%-54.47%-77.68%RDHLRedhill Biopharma-1.39%+9.23%+22.41%-29.00%-86.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYRWFAyr Wellness 2.50Moderate Buy$3.0011,011.11% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYRWFAyr Wellness$463.63M0.01N/AN/A$3.14 per share0.01GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/A($4.12) per shareN/ARDHLRedhill Biopharma$8.04M0.43N/AN/A($3.66) per share-0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYRWFAyr Wellness-$359.31M-$3.26N/AN/AN/A-77.50%-31.73%-11.73%N/AGPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/AQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/12/2025 (Estimated)RDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ALatest GPLB, AYRWF, QLGN, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYRWFAyr WellnessN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYRWFAyr Wellness1.101.600.57GPLBGreen Planet BioengineeringN/AN/AN/AQLGNQualigen TherapeuticsN/A0.710.71RDHLRedhill BiopharmaN/A0.540.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYRWFAyr Wellness0.91%GPLBGreen Planet BioengineeringN/AQLGNQualigen Therapeutics3.18%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipAYRWFAyr Wellness8.10%GPLBGreen Planet BioengineeringN/AQLGNQualigen Therapeutics1.80%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYRWFAyr Wellness2,440116.19 million106.77 millionNot OptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableRDHLRedhill Biopharma2102.30 million2.14 millionNo DataGPLB, AYRWF, QLGN, and RDHL HeadlinesRecent News About These CompaniesRedHill Biopharma Announces First Half 2025 Financial Results and Operational HighlightsSeptember 5, 2025 | prnewswire.comRedHill awarded $1.82M in legal costs and expenses in action against KukboAugust 20, 2025 | msn.comRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment WinAugust 20, 2025 | prnewswire.comRedHill Biopharma receives Talicia licensing payments totaling $1.1MAugust 19, 2025 | msn.comRedHill Received Talicia® Licensing Payments Totaling $1.1 MillionAugust 18, 2025 | prnewswire.comRedHill Biopharma Granted Nasdaq Compliance ExtensionAugust 14, 2025 | msn.comRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's DiseaseJuly 21, 2025 | prnewswire.comRDHL - Redhill Biopharma Ltd ADR Trailing Returns - MorningstarJuly 18, 2025 | morningstar.comMRedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide studyJuly 2, 2025 | msn.comRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerJuly 1, 2025 | prnewswire.comRedHill Biopharma Ltd. (RDHL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18, 2025 | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17, 2025 | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17, 2025 | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, AYRWF, QLGN, and RDHL Company DescriptionsAyr Wellness OTCMKTS:AYRWF$0.03 +0.01 (+22.73%) As of 03:43 PM EasternAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.Green Planet Bioengineering OTCMKTS:GPLB$0.04 0.00 (0.00%) As of 09/9/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.Qualigen Therapeutics NASDAQ:QLGN$1.86 +0.14 (+7.80%) Closing price 03:59 PM EasternExtended Trading$1.90 +0.03 (+1.61%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Redhill Biopharma NASDAQ:RDHL$1.51 +0.09 (+6.34%) Closing price 03:58 PM EasternExtended Trading$1.51 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
